LB Pharmaceuticals Inc Common Stock (LBRX) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 82K | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | -82K | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - |
| Operating Expenses | 22.02M | 13.87M | 5.25M | 5.64M | 5.64M | 16.63M |
| OpEx % of Revenue | - | - | - | - | - | - |
| Selling, General & Admin | 7.38M | 5.39M | 2.83M | 2.62M | 2.62M | 957K |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 14.64M | 8.48M | 2.42M | 2.92M | 2.92M | 15.67M |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 100K | 100K | 0 |
| Operating Income | -22.1M | -13.87M | -5.25M | -5.64M | -5.64M | -16.63M |
| Operating Margin % | - | - | - | - | - | - |
| Operating Income Growth % | -291.64% | - | - | - | 66.06% | - |
| EBITDA | -22.02M | -13.79M | -5.17M | -5.57M | -5.57M | -16.63M |
| EBITDA Margin % | - | - | - | - | - | - |
| EBITDA Growth % | -295.62% | - | - | - | 66.52% | - |
| D&A (Non-Cash Add-back) | 82K | 85K | 81K | 77.5K | 77.5K | 3K |
| EBIT | -22.1M | -13.87M | -5.25M | -5.29M | -5.29M | -16.15M |
| Net Interest Income | 2.85M | 2.8M | 707K | 206.5K | 206.5K | 628K |
| Interest Income | 2.85M | 2.8M | 707K | 0 | 0 | 628K |
| Interest Expense | 0 | 0 | 0 | -206.5K | -206.5K | 0 |
| Other Income/Expense | 3.05M | 2.4M | 1.69M | 555.5K | 555.5K | 474K |
| Pretax Income | -19.05M | -11.47M | -3.56M | -5.09M | -5.09M | -16.15M |
| Pretax Margin % | - | - | - | - | - | - |
| Income Tax | 0 | 1K | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | -0.01% | 0% | 0% | 0% | 0% |
| Net Income | -19.05M | -11.47M | -3.56M | -5.09M | -5.09M | -16.15M |
| Net Margin % | - | - | - | - | - | - |
| Net Income Growth % | -274.45% | - | - | - | 68.5% | - |
| Net Income (Continuing) | -19.05M | -11.47M | -3.56M | -5.09M | -5.09M | -16.15M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.67 | -0.45 | -0.14 | -20.21 | -20.21 | -4.56 |
| EPS Growth % | 96.68% | - | - | - | -343.2% | - |
| EPS (Basic) | -0.67 | -0.45 | -0.14 | -20.21 | -20.21 | -4.56 |
| Diluted Shares Outstanding | 28.24M | 25.3M | 25.3M | 251.79K | 251.79K | 3.54M |
| Basic Shares Outstanding | 28.24M | 25.3M | 25.3M | 251K | 251K | 3.54M |
| Dividend Payout Ratio | - | - | - | - | - | - |